ReviewEuropean journal of medical research2011
Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin:review of the literature.
Review in European journal of medical research, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 46 citations in OpenAlex.
- A Multicenter, Randomized, Open-Label Study to Compare Micafungin with Fluconazole in the Prophylaxis of Invasive Fungal Infections in Living-Donor Liver Transplant Recipients.Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract · 2020Trial
- Micafungin versus anidulafungin in critically ill patients with invasive candidiasis: a retrospective study.BMC infectious diseases · 2016Trial
- Randomized trial of micafungin for the prevention of invasive fungal infection in high-risk liver transplant recipients.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Trial
- Invasive Fungal Infections: The Early Killer after Liver Transplantation.Journal of fungi (Basel, Switzerland) · 2023Article
- Invasive Fungal Breakthrough Infections under Targeted Echinocandin Prophylaxis in High-Risk Liver Transplant Recipients.Journal of fungi (Basel, Switzerland) · 2023Article
- Incidence of Invasive Fungal Infections in Liver Transplant Recipients under Targeted Echinocandin Prophylaxis.Journal of clinical medicine · 2023Article
- [Chinese expert consensus for invasive fungal disease in patients after hematopoietic stem cell transplantation(2023)].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023Article
- Biomaterials for the Prevention of Oral Candidiasis Development.Pharmaceutics · 2021Review
- Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations.European journal of clinical pharmacology · 2020Article
- Retrospective cohort study comparing the risk of severe hepatotoxicity in hospitalized patients treated with echinocandins for invasive candidiasis in the presence of confounding by indication.BMC infectious diseases · 2018Article
- Antifungal activity of oral (Tragacanth/acrylic acid) Amphotericin B carrier for systemic candidiasis: in vitro and in vivo study.Drug delivery and translational research · 2018Article
- Caspofungin Increases Fungal Chitin and Eosinophil and γδ T Cell-Dependent Pathology in Invasive Aspergillosis.Journal of immunology (Baltimore, Md. : 1950) · 2017Article
- Exploring the In Vitro Resistance of Candida parapsilosis to Echinocandins.Mycopathologia · 2016Article
- Influence of echinocandin administration on hemodynamic parameters in medical intensive care unit patients: a single center prospective study.Infection · 2015Article
- Review
- Current concept of abdominal sepsis: WSES position paper.World journal of emergency surgery : WJES · 2014Article
- Invasive fungal infections in the ICU: how to approach, how to treat.Molecules (Basel, Switzerland) · 2014Review
- Guideline for diagnosis, prophylaxis and treatment of invasive fungal infection post burn injury in China 2013.Burns & trauma · 2014Article
- Micafungin: a review of its use in the prophylaxis and treatment of invasive Candida infections.Drugs · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Working by a distinct cell wall-specific mechanism of action, the echinocandin class of antifungals has substantially expanded the range of available treatments for invasive Candida infections. Anidulafungin, caspofungin and micafungin were investigated versus drugs from earlier antifungal classes in large clinical trials that demonstrated their excellent clinical and microbiological efficacy in the primary treatment of invasive candidiasis. Therefore, and supported by a number of favourable pharmacological characteristics, the echinocandins rapidly became established in guidelines and clinical practice as primary treatment options for moderately to severely ill patients with invasive candidiasis. This article reviews the relevant clinical evidence that forms the basis for the use of echinocandins in the management of invasive candidiasis, and discusses their current role in the context of recent guideline recommendations and treatment optimization strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.